- Entry
- $40.97
- Final
- $41.58 +1.5%
- Target
- $132.00
- Score
- +0.01
**CRSP Investment Thesis** **TLDR**: Innovative biotech company that is currently ramping up sales of its new innovative medicine, which is the new standard of care in sickle cell disease. Large pipeline may lead to 50X growth from here according to CEO’s lofty goals. Several catalysts are expected in April/May and June/July timeframe, including updates Q1 earnings (updates on Casgevy sales) and data readouts on clinical programs. Outstanding question: is the healthcare system ready for curative one-time therapies, as compared to …
— ORIGINAL POST ·
CRISPR Tx DD
· r/wallstreetbets
· Mar 18, 2025